前列腺特异性膜抗原正电子发射断层显像引入后转移灶位置及其对新诊断和生化复发前列腺癌患者管理的影响:一项批判性综述
该批判性综述于2022年4月进行非系统性文献检索,总结PSMA-PET在新诊断和复发前列腺癌中定位转移灶的作用。PSMA-PET诊断准确性高于传统影像,骨转移为分期和再分期中最常见部位(分别高达17%和18%),并影响治疗决策,但对癌症死亡率的总体影响尚待评估。
要点
- PSMA-PET在新诊断和复发前列腺癌中诊断准确性均高于传统影像。
- 骨转移是分期和再分期中最常见的转移部位,分别高达17%和18%。
- PSMA-PET高准确性导致显著的患者分期上调并影响临床管理。
核心结论
- PSMA-PET比传统影像或其他PET放射性示踪剂检测到更多病灶,尤其是其他模态未见的转移灶。
- PSMA-PET的高诊断准确性导致显著的患者分期上调并影响临床管理,尽管对癌症死亡率的总体影响尚待评估。
研究设计与样本
- 非系统性文献综述,于2022年4月进行综合检索,文献检索更新至2022年3月。
- 优先总结注册临床试验和多中心合作研究。
主要发现
- PSMA-PET在新诊断前列腺癌和复发疾病中诊断准确性均高于传统影像。
- 这种更高准确性导致更高比例患者被识别为转移性疾病。
- 骨转移报告为分期中最常见转移部位(高达17%),再分期中高达18%。
关键数值与推荐
- 在分期中,考虑根治性手术前淋巴结转移检测灵敏度欠佳,PSMA-PET应仅用于高风险或不利中风险患者,不建议在扫描阴性时常规避免盆腔淋巴结清扫。
- 在前列腺特异性抗原复发时,PSMA-PET在早期检测复发部位方面诊断准确性高于其他诊断程序,从而影响治疗决策过程。
临床怎么用
- PSMA-PET应仅用于高风险或不利中风险患者的分期,不建议在扫描阴性时常规避免盆腔淋巴结清扫。
- 在前列腺特异性抗原复发时,PSMA-PET诊断准确性高于其他诊断程序,影响治疗决策。
局限性
- 对癌症死亡率的总体影响尚待评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The introduction of prostate-specific membrane antigen positron emission tomography (PSMA-PET) had a substantial impact on the management of prostate cancer (PCa) patients with a stage migration phenomenon and consequent treatment changes. OBJECTIVE: To summarise the role of PSMA-PET to define the burden of disease through an accurate location of metastatic site(s) in PCa patients, describing the most common locations at PSMA-PET in the primary staging and recurrence setting, and to assess the clinical impact in the decision-making process. EVIDENCE ACQUISITION: A comprehensive nonsystematic literature review was performed in April 2022. Literature search was updated until March 2022. The most relevant studies have been summarised, giving priority to registered clinical trials and multicentre collaborations. EVIDENCE SYNTHESIS: PSMA-PET showed higher diagnostic accuracy than conventional imaging both in newly diagnosed PCa and in recurrent disease. This greater accuracy led to a migration of a higher proportion of patients identified with metastatic disease. Bone metastases were reported as the most frequent site of metastatic spread in staging (up to 17%) and restaging (up to 18%). In staging, considering the suboptimal sensitivity in lymph node metastasis detection prior to radical surgery, PSMA-PET should be performed in patients with high risk or unfavourable intermediate risk only, and it is not recommended to routinely avoid pelvic lymph node dissection in case of a negative scan. In case of prostate-specific antigen relapse, PSMA-PET had higher diagnostic accuracy than other diagnostic procedures in the early detection of the sites of recurrence, thus influencing the therapy decision-making process. CONCLUSIONS: PSMA-PET detects a higher number of lesions than conventional imaging or other PET radiotracers, especially metastatic lesions unseen with other modalities. The high diagnostic accuracy of PSMA-PET leads to a significant patient upstage and thus an impact in clinical management, even if the overall impact on cancer mortality is still to be assessed. PATIENT SUMMARY: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) identifies metastatic lesions with higher accuracy than conventional imaging, both in primary prostate cancer and during disease recurrence. Skeletal metastasis and extrapelvic lymph nodes are the most common sites of metastatic spread. The high accuracy of PSMA-PET in the detection of metastatic disease led to a significant impact on patient management, even if the overall impact on cancer mortality is still to be assessed.
引用
- Mattana F, Muraglia L, Rajwa P, et al. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review. Eur Urol Oncol. 2023. PMID: 36804735. doi:10.1016/j.euo.2023.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。